KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Restructuring Costs (2016)

Teva Pharmaceutical Industries filings provide 5 years of Restructuring Costs readings, the most recent being $91.0 million for Q4 2016.

  • On a quarterly basis, Restructuring Costs rose 46.77% to $91.0 million in Q4 2016 year-over-year; TTM through Dec 2016 was $289.0 million, a 19.92% increase, with the full-year FY2016 number at $91.0 million, down 50.27% from a year prior.
  • Restructuring Costs hit $91.0 million in Q4 2016 for Teva Pharmaceutical Industries, up from $62.0 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $91.0 million in Q4 2016 to a low of $43.0 million in Q1 2013.
  • Median Restructuring Costs over the past 4 years was $62.0 million (2015), compared with a mean of $66.4 million.
  • Biggest five-year swings in Restructuring Costs: fell 22.5% in 2015 and later surged 46.77% in 2016.
  • Teva Pharmaceutical Industries' Restructuring Costs stood at $43.0 million in 2013, then surged by 86.05% to $80.0 million in 2014, then dropped by 22.5% to $62.0 million in 2015, then skyrocketed by 46.77% to $91.0 million in 2016.
  • The last three reported values for Restructuring Costs were $91.0 million (Q4 2016), $62.0 million (Q4 2015), and $80.0 million (Q4 2014) per Business Quant data.